Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas
UT MD Anderson received Investigational New Drug clearance from the Food and Drug Administration to begin Phase 1 clinical trial
The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today announced that the Food and Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational...
